使用抗增殖细胞核抗原抗体对通过内镜活检获得的胃癌组织标本进行增殖活性分析。

Analysis of proliferative activity using anti-proliferating cell nuclear antigen antibody in gastric cancer tissue specimens obtained by endoscopic biopsy.

作者信息

Yonemura Y, Kimura H, Fushida S, Tugawa K, Nakai Y, Kaji M, Fonseca L, Yamaguchi A, Miyazaki I

机构信息

Surgery II, School of Medicine, Kanazawa University, Japan.

出版信息

Cancer. 1993 Apr 15;71(8):2448-53. doi: 10.1002/1097-0142(19930415)71:8<2448::aid-cncr2820710804>3.0.co;2-v.

DOI:10.1002/1097-0142(19930415)71:8<2448::aid-cncr2820710804>3.0.co;2-v

PMID:8095851

Abstract

BACKGROUND

Proliferative activities of tumors are thought to be prognostic features of malignant tumors, but their value as measured by proliferating cell nuclear antigen (PCNA) labeling remains unclear in gastric cancer.

METHODS

PCNA labeling rates (LR) were quantified in 121 paraffin-embedded biopsy specimens from primary tumors by immunocytochemistry.

RESULTS

Immunohistochemical analyses have demonstrated that PCNA presents an intense staining in the nuclei of tumor cells and mucous neck cells of gastric glands. The PCNA LR ranged from 12% to 79% (mean +/- standard deviation), and a significant correlation was found between bromodeoxyuridine labeling indices and PCNA LR: PCNA LR were closely associated with tumor size, serosal invasion, and nodal involvement. The patients with tumors with high PCNA LR (greater than 40%) were dead significantly earlier than were those with tumors with low PCNA LR: When the PCNA LR and all the clinicopathologic parameters were entered into a Cox regression model, PCNA LR emerged as an independent prognostic factor.

CONCLUSION

These results indicate that PCNA LR may be a potentially useful prognostic factor for gastric cancer.

摘要

背景

肿瘤的增殖活性被认为是恶性肿瘤的预后特征，但在胃癌中，通过增殖细胞核抗原（PCNA）标记所测定的其价值仍不明确。

方法

通过免疫细胞化学对121例来自原发性肿瘤的石蜡包埋活检标本中的PCNA标记率（LR）进行定量分析。

结果

免疫组织化学分析表明，PCNA在胃腺肿瘤细胞和黏液颈细胞的细胞核中呈现强烈染色。PCNA LR范围为12%至79%（均值±标准差），并且发现溴脱氧尿苷标记指数与PCNA LR之间存在显著相关性：PCNA LR与肿瘤大小、浆膜侵犯及淋巴结受累密切相关。PCNA LR高（大于40%）的肿瘤患者死亡时间明显早于PCNA LR低的肿瘤患者：当将PCNA LR和所有临床病理参数纳入Cox回归模型时，PCNA LR成为一个独立的预后因素。